This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Lee, S.-W. Articles by Park, S.-J. Search for Related Content PubMed Articles by Lee, S.-W. Articles by Park, S.-J. Related Collections Related Article

Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus

The DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)

Seung-Whan Lee, MD, PhD^_*, Seong-Wook Park, MD, PhD, FACC^_*,_*, Young-Hak Kim, MD, PhD^_*, Sung-Cheol Yun, PhD^_*, Duk-Woo Park, MD, PhD^_*, Cheol Whan Lee, MD, PhD^_*, Myeong-Ki Hong, MD, PhD^_*, Hyun-Sook Kim, MD, PhD, Jae-Ki Ko, MD, PhD, Jae-Hyeong Park, MD, PhD, Jae-Hwan Lee, MD, Si Wan Choi, MD, In-Whan Seong, MD, PhD, Yoon Haeng Cho, MD, PhD, Nae-Hee Lee, MD, PhD, June Hong Kim, MD, PhD^||, Kook-Jin Chun, MD^|| and Seung-Jung Park, MD, PhD, FACC^_*

^_* Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Chonbuk National University Hospital, Jeonju, Korea
Chungnam National University Hospital, Daejeon, Korea
Soonchunhyang University Bucheon Hospital, Bucheon, Korea
^|| Busan National University Hospital, Busan, Korea.

View larger version (50K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Study Flow During Follow-Up Period After drug-eluting stent randomization, patients were randomly allocated in a 1:1 ratio to the triple antiplatelet group (aspirin, clopidogrel, and cilostazol; triple group) or the dual antiplatelet therapy group (aspirin and clopidogrel; standard group) on the basis of a 2-by-2 factorial design. Six-month angiographic and 9-month clinical outcomes were assessed.